Details

Autor(en) / Beteiligte

• Spennacchio, Antonio
• Lopalco, Antonio
• Racaniello, Giuseppe Francesco
• Cutrignelli, Annalisa
• la Forgia, Flavia Maria
• Fontana, Sergio
• Cristofori, Fernanda
• Francavilla, Ruggiero
• Lopedota, Angela Assunta
• Denora, Nunzio

Titel

Mucoadhesive Budesonide Solution for the Treatment of Pediatric Eosinophilic Esophagitis

Ist Teil von

• Pharmaceuticals (Basel, Switzerland), 2024-05, Vol.17 (5), p.550

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2024

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Eosinophilic Esophagitis is an antigen-mediated inflammatory disease characterized by thickening of the esophageal wall, leading to dysphagia, vomiting, reflux, and abdominal pain. This disease can be treated with a therapeutic approach ranging from diet to pharmacological therapy. Jorveza (budesonide) and Dupixent (dupilumab) are treatments for Eosinophilic Esophagitis approved by the European Medicines Agency in adults but not in children. Budesonide-based extemporaneous oral liquid suspensions could be prepared for pediatric use. The main limit of this formulation is that budesonide needs a longer residence time on the esophageal mucosa to solubilize and diffuse in it to exert its local anti-inflammatory effect. Herein, we propose the development of an extemporaneous mucoadhesive oral budesonide solution for the pediatric population. A liquid vehicle containing hydroxypropyl-beta-cyclodextrin as a complexing agent and carboxymethylcellulose sodium as a mucoadhesive excipient was used to prepare budesonide-based formulations. A stable solution at a concentration of 0.7 mg/mL was successfully prepared and characterized. The formulation showed rheological and mucoadhesive properties suitable for an Eosinophilic Esophagitis local prolonged treatment. In this way, pharmacists can prepare stable budesonide-based mucoadhesive solutions, providing both patients and physicians with a new therapeutic option for Eosinophilic Esophagitis pediatric treatment.